相关实验视频

Updated: Jun 17, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

EV20/Omomyc:一种新的双MYC/HER3针对免疫结合物的新型双MYC/HER3

Sandra Bibbò¹, Emily Capone¹, Giulio Lovato¹

¹Department of Innovative Technologies in Medicine & Dentistry, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy.

Journal of controlled release : official journal of the Controlled Release Society

|August 11, 2024

概括

一种新MYC抑制剂,Omomyc,在癌症治疗中表现有前途. 将Omomyc与抗HER3抗体 (EV20/Omomyc) 结合起来,可以提高其在临床前模型中的向性和有效性,这表明改善了癌症亚型治疗.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物开发药物开发

背景情况:

MYC是人类癌症的关键治疗标,但直接抑制剂的开发一直是具有挑战性的.
组织透MYC抑制剂Omomyc在固体瘤的I期试验中显示出安全性和初步临床活性.
改善MYC抑制剂的向传递可能会增强它们在特定癌症亚型中的治疗潜力.

研究的目的:

通过将其与治疗性抗体结合,研究增强Omomyc的癌症向的潜力.
开发和评估一种免疫结合物,EV20/Omomyc,用于针对性地将Omomyc输送给癌细胞.

主要方法:

通过通过双功能链接器将人性化的抗HER3抗体 (EV20) 与Omomyc结合起来,开发了EV20/Omomyc.
在临床前模型中评估EV20/Omomyc的抗原依赖性透和治疗疗效,特别是转移性神经母细胞瘤模型.

主要成果:

EV20/Omomyc表现出抗原依赖的透,表明有针对性的输送.
免疫结合剂在转移性神经母细胞瘤模型中表现出治疗疗效.
这种方法表明,在特定的癌症征兆中,有可能改善治疗活性.

结论:

使用抗体结合物,如EV20/Omomyc,将Omomyc向特定的癌细胞,可以提高其治疗疗效.
这一策略对治疗特定癌症亚型,包括儿科癌症具有前景.
针对MYC抑制的抗体-药物合物的进一步开发需要进行调查.

关键词:

在HER3中,HER3是HER3.免疫结合剂免疫结合剂这就是MYCNCN.这就是Omomyc Omomyc.目标疗法目标疗法

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cell-mediated Immune Responses

Cell-mediated Immune Responses